Serum Enterolactone Concentration Is Not Associated with Prostate Cancer Risk in a Nested Case-Control Study
Serum Enterolactone Concentration Is Not Associated with Prostate Cancer Risk in a Nested Case-Control Study
Year: 2003
Authors: Kilkkinen, A., Virtamo, J., Virtanen, M.J., Adlercreutz, H., Albanes, D., Pietinen, P.
Publication Name: Cancer Epid. Biomarkers & Prevention
Publication Details: Volume 12; Pages 1209–1212
Abstract:
The lignan enterolactone, produced by the intestinal microflora from dietary precursors, has been
hypothesized to protect against hormone-dependent cancers and cardiovascular diseases. We conducted a nested case-control study to examine the relationship between serum enterolactone concentration and prostate cancer. Enterolactone concentrations were measured by time-resolved fluoroimmunoassay in serum collected at baseline in the a -Tocopherol, b-Carotene Cancer Prevention Study from 214 men with prostate cancer diagnosed during a 6-year follow-up and from 214 controls matched by age, date of baseline blood collection, intervention group, and local study area. Mean serum enterolactone concentration (in nmol/liter) did not differ significantly between case and control subjects [15.9 (SD, 15.2) versus 16.9 (SD, 14.9), respectively (P = 0.42)]. Odds ratios for prostate cancer risk estimated by conditional logistic regression for increasing quartiles of enterolactone concentration were 1.00 (referent), 0.72 [95% confidence interval (CI), 0.43–1.23], 0.98 (95% CI, 0.58 –1.68), and 0.71 (95% CI, 0.42–1.21). Our findings do not support the hypothesis that enterolactone is involved in the development of prostate cancer. Author's Abstract.
hypothesized to protect against hormone-dependent cancers and cardiovascular diseases. We conducted a nested case-control study to examine the relationship between serum enterolactone concentration and prostate cancer. Enterolactone concentrations were measured by time-resolved fluoroimmunoassay in serum collected at baseline in the a -Tocopherol, b-Carotene Cancer Prevention Study from 214 men with prostate cancer diagnosed during a 6-year follow-up and from 214 controls matched by age, date of baseline blood collection, intervention group, and local study area. Mean serum enterolactone concentration (in nmol/liter) did not differ significantly between case and control subjects [15.9 (SD, 15.2) versus 16.9 (SD, 14.9), respectively (P = 0.42)]. Odds ratios for prostate cancer risk estimated by conditional logistic regression for increasing quartiles of enterolactone concentration were 1.00 (referent), 0.72 [95% confidence interval (CI), 0.43–1.23], 0.98 (95% CI, 0.58 –1.68), and 0.71 (95% CI, 0.42–1.21). Our findings do not support the hypothesis that enterolactone is involved in the development of prostate cancer. Author's Abstract.
